You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Optimized lactoferrin for treatment of intracerebral hemorrhage

    SBC: Pharmareview Corporation            Topic: NINDS

    DESCRIPTION provided by applicant Intracerebral hemorrhage ICH is a major public health problem with highest mortality rate of all stroke subtypes and long term disability Since there are no available FDA approved therapies for ICH it is of enormous importance to establish effective treatment for this medical condition Following ICH the deposited blood is damaging initially via compression ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Ovarian cancer using novel nanoparticle formulations

    SBC: KIROMIC BIOPHARMA INC            Topic: 102

    DESCRIPTION provided by applicant Ovarian cancer is the fifth most leading cause of cancer related deaths in women in the US It has been observed that the cancer relapses within relatively short periods of time even after the surgery and chemotherapy Therefore immunotherapeutic strategies may serve as an alternative to control the recurrence or progression of ovarian cancer Oral vaccines ar ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. A Rapid assay for RNA targeted drugs: Instrumentation Supplement

    SBC: NUBAD LLC            Topic: 300

    DESCRIPTION provided by applicant Some of the most significant therapies that treat disease target nucleic acids Drugs that target nucleic acid include cancer drugs antibiotics and antivirals Combined these classes of drugs have annual sales worldwide of $ billion Antibiotics that target nucleic acids account for $ billion of the $ billion of sales annuall for all antibiotics an ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Novel S. aureus Antibiotics with Reduced Resistance Susceptibility

    SBC: NOVALEX THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Widespread antibiotic use has accelerated S aureus resistance to almost all marketed antibiotic classes including beta lactams fluoroquinolones macrolides aminoglycosides tetracyclines as well as the newer linezolid and daptomycin Methicillin resistant S aureus MRSA is an increasing public health threat with deaths from MRSA infections already compar ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Development of broad spectrum Hepatitis C Virus NS3/4A protease inhibitors

    SBC: NOVALEX THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant This is a collaborative proposal to develop inhibitors with reduced susceptibility to resistance and improved genotype spectrum of activity against the NS A protease of the Hepatitis C virus HCV Over three percent of the worldandapos s population is infected with the hepatitis C virus HCV Unfortunately the current best treatment is still quite challeng ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Reversal of Myocardial Infarction by Localized Stimulation

    SBC: Micro Vide, LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Heart attacks i e myocardial infarction or MI occur in more than million patients annually Advances in pharmacological therapy have dramatically improved survival following the initial MI Consequently the number of patients with previous MI continues to increase and as a result put in jeopardy millions of patients for development of heart failure I ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Assessing the Bite Counter as a Tool for Food Intake Monitoring: Phase II

    SBC: BITE TECHNOLOGIES, LLC            Topic: 300

    DESCRIPTION provided by applicant Self monitoring has been described as the andquot cornerstone of the behavioral treatment of obesityandquot Consistent self monitoring of energy intake is associated with improved dietary adherence and weight loss and maintenance The problem is that individuals are notoriously bad at self monitoring their intake and suffer from an underreporting bias The s ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Ex vivo purging strategy for treatment of multiple myeloma

    SBC: DNATRIX INC            Topic: NCI

    DESCRIPTION (provided by applicant): The ultimate goal of this application is to develop a novel ex vivo purging method using myxoma virus (MYXV), a rabbit-specific poxvirus, to improve the clinical outcomes in treatment of multiple myeloma (MM). MM is aclonal plasma cell malignancy that has to date resisted essentially all therapeutic strategies. Currently, the standard of care for patients wit ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government